Special Issue

Integrative Metabolomic Biomarkers for Neurodegeneration

Message from the Guest Editor

The biomarkers of neurodegeneration have played an increasingly important role in predicting the disease risk, establishing a diagnosis, predicting the treatment response, monitoring the disease progression, serving as drug targets, and enabling prognosis determination. Furthermore, the discovery of new biomarkers can shed light on the physiological mechanisms of neurodegeneration. The search for neurodegenerative biomarkers is actively ongoing. It is hoped that easily clinically assessable biomarkers will facilitate the earlier diagnosis of neurodegeneration, leading to improved therapies.

The connection between biomarkers and biological phenomena is strengthened when integrated with multiomics data. Furthermore, the introduction of machine learning to integrative multi-omics data has helped to uncover novel biomarkers for disease.

The possible topics of this Special Issue include the use of integrative metabolomics to discover novel metabolite biomarkers, to describe new insights into current metabolic biomarkers, to propose novel approaches for improving the quality of data and integration of metabolomics, and to leverage metabolomic biomarkers as drug targets.


Guest Editor

Dr. Robert Logan

Ginger Judge Science Center, Biology & Biotechnology Department, School of Science and Technology, Endicott College, Beverly, MA, USA

Deadline for manuscript submissions

closed (30 April 2025)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/203153

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

